Table 1.

Distribution of age, gender and positivity for immunohistochemical biomarkers

	All (n = 155)	CRC (n = 83)	CCC (n = 29)	EGJ (n = 15)	PDAC (n = 13)	HCC (n = 4)	Others (n = 11)
Age [yrs]
Median (Range)	61 (24–90)	60 (25–90)	63 (38–78)	58 (24–84)	62 (39–82)	58 (49–64)	63 (32–81)
Gender, n [%]
Male	98 [63%]	45 [54%]	20 [69%]	13 [87%]	7 [54%]	4 [100%]	9 [82%]
Female	57 [37%]	38 [46%]	9 [31%]	2 [13%]	6 [46%]	0	2 [18%]
Mismatch repair status, n [%]
pMMR	121 [78%]	74 [89%]	21 [73%]	13 [87%]	7 [54%]	0	6 [55%]
dMMR	7 [5%]	5 [6%]	1 [3%]	0	0	0	1 [9%]
ND	27 [17%]	4 [5%]	7 [24%]	2 [13%]	6 [46%]	4 [100%]	4 [36%]
Her2-status, n [%]
Her2-negative	55 [36%]	22 [27%]	13 [45%]	13 [87%]	3 [23%]	0	4 [36%]
Her2-positive	0	0	0	0	0	0	0
ND	100 [64%]	61 [73%]	16 [55%]	2 [13%]	10 [77%]	4 [100%]	7 [64%]

Abbreviations: CRC Colorectal cancer, CCC Cholangiocellular carcinoma, EGJ Esophagogastric junction adenocarcinoma, PDAC pancreatic ductal adenocarcinoma, HCC Hepatocellular carcinoma, pMMR proficient mismatch repair, dMMR deficient mismatch repair, ND Not determined